Difficulties on the access to innovative targeted therapies for lung cancer in Spain
ConclusionSLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Spain Health | Websites